Biotest AG
Company Presentation
May 2013

Company Presentation EU

Biotest AG

0
Disclaimer
•

•
•

•
•

This document contains forward-looking statements on overall economic development as
well as on th...
Biotest Group

 Headquarter in Dreieich/Germany
(Frankfurt area)
 Subsidiaries in 11 countries worldwide
 Employees (FT...
Shareholder structure

Biotest AG
Ordinary shares: 6.6 mio

Preference shares: 6.6 mio

with voting rights

no voting righ...
Biotest: History and milestones achieved

1946: Biotest- 1961: New
Serum Institut production
1987: IPO
GmbH
facility at
Dr...
From plasma to a medicinal product

§§§
Products
Safety - Quality
Coagulation Factors
Immunoglobulins
Plasma
Donation

Fil...
Biotest production sites
Biotest produces in Dreieich (near Frankfurt) and in Boca Raton, Florida,USA
1.800 employees worl...
Three strategic areas of therapy: Products - Pipeline
Clinical

Haematology

Intensive Care

Immunology

Products
Haemocti...
Continue and accelerate growth
Biotest Group: Sales 2004-2012 (€ million)*

Sales target
for 2020:

500
440.0
400

~ € 1 b...
Biotest guidance in 2013
Sales growth 10 – 15% vs. 2012
+10-15%

(EURm)

500

EBIT growth 10 – 15% vs. 2012

(EURm)

60

+...
Very strong balance sheet and share performance
Share price preference shares
 With the successful capital
increase Biote...
Addresses of group figures – internal and external
• Bank Analysts
• Investors
• Shareholders
• Banks
• Supervisory Board
...
Challenges in reporting
• Harmonisation of the external and internal
reporting

• One database of all departments
• Differ...
Time Schedule

Q1

2012
Q2
Q3

Q4

Q1

2013
Q2
Q3

Q4

Analysis Mgmt-Reporting
Reqiurements Financial Consolidation

Proof...
Zielarchitektur für Controlling und Finance
Oberfläche
(User-Interface)
Mobiles
Reporting

Basis für eine
erfolgreiche und...
Modell Legale Konsolidierung

Company Presentation EU

Biotest AG

15
Anbindung der operativen SAP-Systeme
SAP
ERP

FI-GL

SAP BW

FI-Bilanz
Reporting

FI-GL
Agregations
Cube

SAP BPC

FI
Mapp...
Manuelle Erfassungslayouts
•

Transparente Datenerfassung für Non-SAP Gesellschaften

•

Anwendungsfreundliche und bekannt...
Lessons learned
•

Abstimmung und Vereinheitlichung der Abschlussprozesse

•

Definition einheitlicher Kennzahlen

•

Oper...
Haben Sie Fragen?

Biotest AG

Company Presentation EU

20
Contact
Biotest AG:

IBsolution GmbH:

Dirk Neumüller
Director Group Reporting

Thomas Eichelbaum
Project Manager

Phone:
...
Upcoming SlideShare
Loading in …5
×

BI Symposium: Erfüllung strenger Berichtspflichten mit flexiblen, hochadaptiven Controllingwerkzeugen – Integration des internen und externen Berichtswesens bei der Biotest AG

1,007 views

Published on

Erfüllung strenger Berichtspflichten mit flexiblen, hochadaptiven Controllingwerkzeugen – Integration des internen und externen Berichtswesens bei Biotest

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,007
On SlideShare
0
From Embeds
0
Number of Embeds
36
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

BI Symposium: Erfüllung strenger Berichtspflichten mit flexiblen, hochadaptiven Controllingwerkzeugen – Integration des internen und externen Berichtswesens bei der Biotest AG

  1. 1. Biotest AG Company Presentation May 2013 Company Presentation EU Biotest AG 0
  2. 2. Disclaimer • • • • • This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and thus are subject to risks and elements of uncertainty that could result in deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. All figures reported relate to the Continuing Operations of the Biotest Group. After the sale of the Medical Diagnostic activities to Bio-Rad Laboratories Inc. and the sale of the segment Microbiological Monitoring to Merck KGaA, both activities are being reported as Discontinued Operation All comparative figures relate to the corresponding last year´s period, unless stated otherwise. The information contained herein serves information purposes and does not constitute any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities. In case of a future offering it should be noted that such offered securities will solely be offered on the basis of an approved securities prospectus. Any investment decision should only be made based on the information contained in such prospectus. Company Presentation EU Biotest AG 1
  3. 3. Biotest Group  Headquarter in Dreieich/Germany (Frankfurt area)  Subsidiaries in 11 countries worldwide  Employees (FTE)*: 1,834 Thereof 48% located outside Germany  Founded in 1946, IPO in 1987, SDAX in 2007 (preference shares)  Biotest shares:  6,595,242 ordinary shares  6,595,242 preference shares Headquarter, Dreieich *: as of June 30, 2013 Company Presentation EU Biotest AG 2
  4. 4. Shareholder structure Biotest AG Ordinary shares: 6.6 mio Preference shares: 6.6 mio with voting rights no voting rights, but higher dividend OGEL GmbH*: KSK Biberach*: 50.03% ~24% Free Float: ~26% Free Float: 100% 50.0% of total capital, and 100% of voting rights 50.0% of total capital, 0% of voting rights * as of June 2013 based on notifications Company Presentation EU Biotest AG 3
  5. 5. Biotest: History and milestones achieved 1946: Biotest- 1961: New Serum Institut production 1987: IPO GmbH facility at Dreieich 1991: Start of 1968: First Microbiological subsidiary Monitoring outside Germany 2004: Start of 1948: (Italy) modernized Test-Serum Plasma Proteins Anti-D 1971: Market production launch of Intraglobin® 2010: Divestment of Medical Diagnostics 2011: - Divestment of Microbiological Monitoring - Biotest- AbbVie Deal for BT 061 2012: Bivigam® Launch in US 2013 1946 Company Presentation EU 2007: - Clinical testing of monoclonal antibodies - Acquisition of Nabi - Preference share in SDAX Biotest AG 4
  6. 6. From plasma to a medicinal product §§§ Products Safety - Quality Coagulation Factors Immunoglobulins Plasma Donation Filling & FracPurification Packaging tionation Hyperimmunoglobulins Human Albumin Supervised and regulated by v. Paul-Ehrlich Institut, FDA etc. Company Presentation EU Biotest AG • effective • safe • natural 5
  7. 7. Biotest production sites Biotest produces in Dreieich (near Frankfurt) and in Boca Raton, Florida,USA 1.800 employees worldwide CapEx per year: approx. € 35 Mio. Production site Dreieich Company Presentation EU Production site Florida, USA Biotest AG 6
  8. 8. Three strategic areas of therapy: Products - Pipeline Clinical Haematology Intensive Care Immunology Products Haemoctin® Haemonine® Intratect® Hepatect® , Nabi-HB® Zutectra® Cytotect® Varitect® Bivigam ® Pentaglobin® Humanalbumine Biseko® Cofact® Pipeline BT-062 Fovepta® Civacir® Cytotect 70 (BT-094) IgM-Concentrate Fibrinogen Tregalizumab (BT-061) Company Presentation EU Biotest AG 7
  9. 9. Continue and accelerate growth Biotest Group: Sales 2004-2012 (€ million)* Sales target for 2020: 500 440.0 400 ~ € 1 billion 339.4 300 200 141.9 100 0 2004 1 2005 2 2006 3 2007 4 2008 2009 5 6 2010 7 2011 8 2012 9 * On a comparable basis, only pharmaceutical activities Company Presentation EU Biotest AG 8
  10. 10. Biotest guidance in 2013 Sales growth 10 – 15% vs. 2012 +10-15% (EURm) 500 EBIT growth 10 – 15% vs. 2012 (EURm) 60 +4.3% 400 +7.5% 40 300 200 +10-15% 422 440 41,6 44,7 2011 20 2012 100 0 0 2011 Company Presentation EU 2012 2013e Biotest AG 2013e 9
  11. 11. Very strong balance sheet and share performance Share price preference shares  With the successful capital increase Biotest is well prepared for new investments in expanding our capacity + 64.8% in one year  High equity portion of 61% allows a high debt capacity  Higher number of shares outstanding and new investors should lead to an increased liquidity in our shares Sources: Handelsblatt.com 12.09.2013 Company Presentation EU Biotest AG 10
  12. 12. Addresses of group figures – internal and external • Bank Analysts • Investors • Shareholders • Banks • Supervisory Board • Management Board Company Presentation EU Biotest AG 11
  13. 13. Challenges in reporting • Harmonisation of the external and internal reporting • One database of all departments • Different IT-Structure in 16 subsidiaries in 11 countries • Preparation for increasing M&A transactions in the future Company Presentation EU Biotest AG 12
  14. 14. Time Schedule Q1 2012 Q2 Q3 Q4 Q1 2013 Q2 Q3 Q4 Analysis Mgmt-Reporting Reqiurements Financial Consolidation Proof-of-Concept Software-Selection User Requirements Requirements Specification Functional Design Detail-IT-Conception Implementation SalesTool Implementation Leg. Consolidation Implementation Mgmt-Tool Go Live As-is Analysis Review Process Company Presentation EU Biotest AG Decision Softwaretool Kick-off Project Starting GoLive Step-by-Step 13
  15. 15. Zielarchitektur für Controlling und Finance Oberfläche (User-Interface) Mobiles Reporting Basis für eine erfolgreiche und nachhaltige Unternehmenssteuerung Standard/HochglanzReporting Dashboards, Cockpits Ad-Hoc-Abfragen „Listen“, progr. Abfragen (Unternehmens)Planung (Sales, Budget, Finance, …) Controlling Finance/ Konsolidierung Gemeinsamen Datenbasis aller Controlling und Finance Daten aus allen Biotest BGs XLS-Upload/ Man.Eingabe Automatische Datenübernahme Operative Systeme und Prozesse der BGs Company Presentation EU SAP ECC 6.0 SAP R/3 4.7 Biotest AG FlatFile Upload Non-SAP 14
  16. 16. Modell Legale Konsolidierung Company Presentation EU Biotest AG 15
  17. 17. Anbindung der operativen SAP-Systeme SAP ERP FI-GL SAP BW FI-Bilanz Reporting FI-GL Agregations Cube SAP BPC FI Mapping Cube MAPPING ERP to SAP BPC PreConsolidation Cube CO-PA Dreieich CO-PA BGs /CPMB/CONSOLIDATION BPC- Cube CO-PA Reporting CO-PA Agregations Cube CO-PA Mapping Cube CO-PA Reporting Company Presentation EU Biotest AG 17
  18. 18. Manuelle Erfassungslayouts • Transparente Datenerfassung für Non-SAP Gesellschaften • Anwendungsfreundliche und bekannte Benutzeroberfläche • Nachvollziehbare Datenanpassungen • Flexible Anpassungen bei neuen Strukturen oder neune gesetzlichen Anforderungen Company Presentation EU Biotest AG 18
  19. 19. Lessons learned • Abstimmung und Vereinheitlichung der Abschlussprozesse • Definition einheitlicher Kennzahlen • Operative Buchungsvorschriften für Detailauswertungen • Anwenderfreundlichkeit • Transparente und revisonssichere Prozesse • Testvorgehen / Aufsatzpunkt Nachfahren der Altabschlüsse Company Presentation EU Biotest AG 19
  20. 20. Haben Sie Fragen? Biotest AG Company Presentation EU 20
  21. 21. Contact Biotest AG: IBsolution GmbH: Dirk Neumüller Director Group Reporting Thomas Eichelbaum Project Manager Phone: E-Mail: Phone: E-Mail: +49 (0) 6103 - 801 -269 dirk_neumueller@biotest.de Company Presentation EU Biotest AG +49 (0) 7131 - 2711 -1087 thomas.eichelbaum@ibsolution.de 21

×